<VariationArchive RecordType="classified" VariationID="1353481" VariationName="NM_024570.4(RNASEH2B):c.129dup (p.Cys44fs)" VariationType="Duplication" Accession="VCV001353481" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-12-25" DateCreated="2022-03-28" MostRecentSubmission="2022-03-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1499480" VariationID="1353481">
      <GeneList>
        <Gene Symbol="RNASEH2B" FullName="ribonuclease H2 subunit B" GeneID="79621" HGNC_ID="HGNC:25671" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>13q14.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="50909678" stop="50970460" display_start="50909678" display_stop="50970460" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="51483813" stop="51544595" display_start="51483813" display_stop="51544595" Strand="+" />
          </Location>
          <OMIM>610326</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_024570.4(RNASEH2B):c.129dup (p.Cys44fs)</Name>
      <CanonicalSPDI>NC_000013.11:50927467:CCCC:CCCCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>13q14.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="50927467" stop="50927468" display_start="50927467" display_stop="50927468" variantLength="1" positionVCF="50927467" referenceAlleleVCF="A" alternateAlleleVCF="AC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="51501603" stop="51501604" display_start="51501603" display_stop="51501604" variantLength="1" positionVCF="51501603" referenceAlleleVCF="A" alternateAlleleVCF="AC" />
      </Location>
      <ProteinChange>C44fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_279" sequenceAccession="LRG_279">
            <Expression>LRG_279:g.22716dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_279t1" sequenceAccession="LRG_279t1">
            <Expression>LRG_279t1:c.129dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_279p1" sequenceAccession="LRG_279p1" change="p.Cys44fs">
            <Expression>LRG_279p1:p.Cys44fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.10" sequenceAccession="NC_000013" sequenceVersion="10" change="g.51501607dup" Assembly="GRCh37">
            <Expression>NC_000013.10:g.51501607dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.11" sequenceAccession="NC_000013" sequenceVersion="11" change="g.50927471dup" Assembly="GRCh38">
            <Expression>NC_000013.11:g.50927471dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009055.1" sequenceAccession="NG_009055" sequenceVersion="1" change="g.22716dup">
            <Expression>NG_009055.1:g.22716dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001142279.2" sequenceAccession="NM_001142279" sequenceVersion="2" change="c.129dup">
            <Expression>NM_001142279.2:c.129dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001135751.1" sequenceAccession="NP_001135751" sequenceVersion="1" change="p.Cys44fs">
            <Expression>NP_001135751.1:p.Cys44fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_024570.4" sequenceAccession="NM_024570" sequenceVersion="4" change="c.129dup" MANESelect="true">
            <Expression>NM_024570.4:c.129dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_078846.2" sequenceAccession="NP_078846" sequenceVersion="2" change="p.Cys44fs">
            <Expression>NP_078846.2:p.Cys44fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2137925083" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_024570.4(RNASEH2B):c.129dup (p.Cys44fs) AND Aicardi-Goutieres syndrome 2" Accession="RCV001863437" Version="1">
        <ClassifiedConditionList TraitSetID="336">
          <ClassifiedCondition DB="MedGen" ID="C3489724">Aicardi-Goutieres syndrome 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-06-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-06-06" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2022-03-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17846997</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="336" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="95" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Aicardi-Goutieres syndrome 2</ElementValue>
                <XRef ID="MONDO:0012429" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AGS2</ElementValue>
                <XRef Type="MIM" ID="610181" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15472" />
                <XRef ID="15472" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Most characteristically, Aicardi-Gouti√®res syndrome (AGS) manifests as an early-onset encephalopathy that usually, but not always, results in severe intellectual and physical disability. A subgroup of infants with AGS present at birth with abnormal neurologic findings, hepatosplenomegaly, elevated liver enzymes, and thrombocytopenia, a picture highly suggestive of congenital infection. Otherwise, most affected infants present at variable times after the first few weeks of life, frequently after a period of apparently normal development. Typically, they demonstrate the subacute onset of a severe encephalopathy characterized by extreme irritability, intermittent sterile pyrexias, loss of skills, and slowing of head growth. Over time, as many as 40% develop chilblain skin lesions on the fingers, toes, and ears. It is becoming apparent that atypical, sometimes milder, cases of AGS exist, and thus the true extent of the phenotype associated with pathogenic variants in the AGS-related genes is not yet known.</Attribute>
                <XRef ID="NBK1475" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10894" />
                <XRef ID="10894" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301648</ID>
                <ID Source="BookShelf">NBK1475</ID>
              </Citation>
              <XRef ID="51" DB="Orphanet" />
              <XRef ID="C3489724" DB="MedGen" />
              <XRef ID="MONDO:0012429" DB="MONDO" />
              <XRef Type="MIM" ID="610181" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4129920" SubmissionDate="2022-03-23" DateLastUpdated="2022-03-28" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="14020693|MedGen:C3489724" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002109280" DateUpdated="2022-03-28" DateCreated="2022-03-28" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-06-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17846997</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Cys44Leufs*19) in the RNASEH2B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RNASEH2B are known to be pathogenic (PMID: 17846997). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with RNASEH2B-related conditions. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RNASEH2B" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.51501603_51501604insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3489724" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4129920" TraitType="Disease" MappingType="XRef" MappingValue="C3489724" MappingRef="MedGen">
        <MedGen CUI="C3489724" Name="Aicardi-Goutieres syndrome 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

